Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | June 10, 2025 | June 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date June 10, 2025 · Filed June 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,955 |
Reported balance
After 2025-06-10 transaction · row 1
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 7,828 · Balance 77,955 F1: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2025 Filed Jun 12, 2025 20:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 7,828 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002140 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,955 F1 · shares: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 18:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 276 | $6.63 | $1,829.88 |
DisclosureSEC source: 0000905148-24-002306 · form4.xml · nonDerivative · entry 2 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,127 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 18:27 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 2,762 | $6.63 | $18,309.30 |
DisclosureSEC source: 0000905148-24-002306 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,403 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2024 and August 19, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. F3 · balance_after: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 18:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 7,075 | $0.00 Strike: $427.63 | $0.00 |
DisclosureSEC source: 0000905148-24-002244 · form4.xml · derivative · entry 3 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,075 shares Expires 2031-02-28 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. F3 · derivative.exercise_date: 1/48th of the shares subject to the stock option vested and became exercisable each month with the initial installment vesting on April 1, 2021, subject to the reporting person's continuous service. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 18:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 9,680 | $0.00 Strike: $303.75 | $0.00 |
DisclosureSEC source: 0000905148-24-002244 · form4.xml · derivative · entry 2 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,680 shares Expires 2030-02-28 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vested and became exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 18:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $510.75 | $0.00 |
DisclosureSEC source: 0000905148-24-002244 · form4.xml · derivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2029-06-24 F4 · price: This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on June 24, 2020, and the remaining shares vested in equal monthly installments over the following 36 months. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:34 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 81,506 | $0.62 | $50,289.20 |
DisclosureSEC source: 0000905148-24-001561 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,829,146 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2024 and May 17, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 18:19 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 24,844 | $0.72 | $17,887.68 |
DisclosureSEC source: 0000905148-24-000911 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,910,652 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 4, 2024 and March 5, 2024 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 16:41 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 1,280,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-000115 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,935,496 F1 · shares: These restricted stock units vest as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the second Quarterly Vesting Date (as defined below) following January 8, 2024, and as to 1/8th of the total number of shares (rounded down to the next whole number of shares) on the next seven Quarterly Vesting Dates, such that all of the shares shall be vested on the last Quarterly Vesting Date, subject to the reporting person's continuous service. "Quarterly Vesting Date" means March 1, May 15, August 15, and November 15 of each year, provided that if such date falls on a weekend or holiday, the Quarterly Vesting Date shall be the first business day after such date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 17:31 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 20,409 | $0.39 | $7,939.10 |
DisclosureSEC source: 0000905148-23-001513 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 655,496 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 18:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 9,334 | $1.65 | $15,429.10 |
DisclosureSEC source: 0001140361-23-040562 · form4.xml · nonDerivative · entry 2 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,905 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 18:25 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 21,432 | $1.65 | $35,405.66 |
DisclosureSEC source: 0001140361-23-040562 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 685,239 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 16:15 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 14,291 | $1.66 | $23,723.06 |
DisclosureSEC source: 0001140361-23-032216 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 706,671 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 29,766 | $2.04 | $60,633.34 |
DisclosureSEC source: 0001140361-23-025559 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,962 F1 · kind: Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 16, 2023 and May 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 18:49 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 15,679 | $3.63 | $56,867.73 |
DisclosureSEC source: 0001567619-23-004540 · doc1.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,728 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 730,600 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001140361-23-010102 · form4.xml · derivative · entry 2 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,600 Underlying: Common Stock · 730,600 shares Expires 2033-02-28 F2 · derivative.exercise_date: 1/36th of the shares subject to the stock option vest and become exercisable each month, with the initial installment vesting on April 1, 2023, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 17:16 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 324,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-010102 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 766,407 F1 · shares: These restricted stock units vest in 12 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2023, subject to the reporting person's continuous service. "Company Quarterly Vesting Date" means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 20:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 15,591 | $4.49 | $70,003.59 |
DisclosureSEC source: 0001140361-22-042380 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 441,696 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2022 and November 17, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 18:24 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 14,806 | $5.04 | $74,548.21 |
DisclosureSEC source: 0001140361-22-030302 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,287 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 16:48 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 14,220 | $7.20 | $102,384.00 |
DisclosureSEC source: 0001567619-22-013481 · doc1.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,093 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. Read SEC document |
| May 17, 2022 Filed May 19, 2022 17:04 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 13,913 | $5.32 | $73,961.51 |
DisclosureSEC source: 0001140361-22-019978 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,313 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 17, 2022 and May 18, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 19:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 339,419 | $0.00 Strike: $10.21 | $0.00 |
DisclosureSEC source: 0001140361-22-007764 · form4.xml · derivative · entry 3 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,419 Underlying: Common Stock · 339,419 shares Expires 2032-02-28 F4 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2022, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 19:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,828 | $9.86 | $87,008.77 |
DisclosureSEC source: 0001140361-22-007764 · form4.xml · nonDerivative · entry 2 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,226 F2 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units. F3 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 1, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 19:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 180,565 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-007764 · form4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,054 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2022, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 17:55 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,402 | $17.12 | $143,816.19 |
DisclosureSEC source: 0001567619-21-020781 · doc1.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,489 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 16, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. The prices actually received ranged from $16.45 to $17.3823. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold on behalf of the group at each price within the range. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 19:37 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,223 | $12.53 | $103,050.64 |
DisclosureSEC source: 0001567619-21-016151 · doc1.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,891 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2021 and August 18, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| June 25, 2021 Filed Jun 29, 2021 16:06 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 14,194 | $16.32 | $231,660.27 |
DisclosureSEC source: 0001567619-21-012695 · doc1.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,114 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. Read SEC document |
| May 18, 2021 Filed May 20, 2021 16:31 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 8,313 | $14.55 | $120,954.15 |
DisclosureSEC source: 0001209191-21-034425 · doc4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,308 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2021 and May 19, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 16:06 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,887 | $16.74 | $81,808.38 |
DisclosureSEC source: 0001209191-21-017768 · doc4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,621 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2021 and March 3, 2021 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 176,886 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-21-017030 · doc4.xml · derivative · entry 2 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,886 Underlying: Common Stock · 176,886 shares Expires 2031-02-28 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2021, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 17:13 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 117,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017030 · doc4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,508 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2021, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 16:07 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,716 | $19.77 | $93,254.18 |
DisclosureSEC source: 0001209191-20-059044 · doc4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,321 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 17, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| August 18, 2020 Filed Aug 20, 2020 19:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 4,807 | $12.09 | $58,116.63 |
DisclosureSEC source: 0001209191-20-047821 · doc4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,037 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 18, 2020 and August 19, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 16:18 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 12,135 | $12.92 | $156,784.20 |
DisclosureSEC source: 0001209191-20-039077 · doc4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,844 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. Read SEC document |
| May 18, 2020 Filed May 20, 2020 18:10 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | SaleCommon Stock | 3,195 | $11.22 | $35,847.90 |
DisclosureSEC source: 0001209191-20-031004 · doc4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,979 F1 · kind: Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted Restricted Stock Units. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on May 18, 2020 and May 19, 2020 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 16:59 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 242,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001209191-20-015349 · doc4.xml · derivative · entry 2 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,000 Underlying: Common Stock · 242,000 shares Expires 2030-02-28 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 16:59 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015349 · doc4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,174 F1 · shares: These restricted stock units vest in 16 equal quarterly installments on each Company Quarterly Vesting Date (as defined below), with the initial installment vesting on May 15, 2020, subject to the reporting person's continuous service. Company Quarterly Vesting Date means March 1, May 15, August 15 and November 15 of each year. Read SEC document |
| January 24, 2020 Filed Jan 28, 2020 16:31 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 9,900 | $13.62 | $134,838.00 |
DisclosureSEC source: 0001209191-20-005140 · doc4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,174 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 16:20 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $20.43 | $0.00 |
DisclosureSEC source: 0001209191-19-038914 · doc4.xml · derivative · entry 2 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2029-06-24 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on June 24, 2020 and the remaining shares vest in equal monthly installments over the following 36 months. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 16:20 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 140,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-038914 · doc4.xml · nonDerivative · entry 1 Touchon Pascal · CIK 0001780060 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,074 F1 · shares: 27,574 of the shares subject to restricted stock units vest in full on January 24, 2020. 28,125 of the shares subject to restricted stock units vest on June 24, 2020 and the remaining shares vest in equal annual installments over the following 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.